A pilot study to search possible mechanisms of ultralong gonadotropin-releasing hormone agonist therapy in IVF-ET patients with endometriosis

Hiroshi Tamura, Akihisa Takasaki, Yasuhiko Nakamura, Fumitaka Numa, Norihiro Sugino
Journal of ovarian research · 2014 · vol. 7(1) , pp. 100 · doi:10.1186/s13048-014-0100-8 · PMID:25331066 · W2136042235
article OA: gold CC0 ⤵ 41 in-corpus citations
📄 Open PDF View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-08 ⓘ

Ultralong GnRHa therapy in IVF-ET patients with endometriosis reduced intrafollicular tumor necrosis factor alpha, oxidative stress markers, and increased antioxidant concentrations.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-08 ⓘ

This pilot study compared ultralong GnRH agonist (GnRHa) therapy versus standard mid-luteal GnRHa down-regulation in 23 infertile women with Stage III or IV endometriosis undergoing IVF-ET, focusing on intrafollicular TNFα and oxidative stress markers (8-OHdG, HEL) and antioxidants (melatonin, Cu,Zn-SOD), along with IVF outcomes. The ultralong group received three courses of buserelin acetate followed by controlled ovarian hyperstimulation, while the control group received mid-luteal GnRHa down-regulation; implantation and pregnancy rates tended to be higher in the ultralong group, but mature follicle numbers, retrieved oocytes, and fertilization rates were not different. Follicular fluid TNFα and 8-OHdG were significantly lower with ultralong therapy, and melatonin was significantly higher, while the study’s limited sample size and pilot design constrain conclusions. This paper is centrally about endometriosis — it investigates how ultralong GnRHa might reduce intrafollicular inflammatory cytokines and oxidative stress in IVF-ET patients with endometriosis.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

BACKGROUND: Additional treatment with a gonadotropin-releasing hormone (GnRH) agonist (GnRHa) before IVF-ET (ultralong GnRHa therapy) has been reported to improve the outcome of IVF-ET in endometriosis patients. However, the mechanism of ultralong GnRHa therapy is unclear. It is suggested that inflammatory cytokines and oxidative stress contribute to infertility in endometriosis patients. Therefore, in order to search a possible mechanism of ultralong GnRHa therapy, we investigated the effect of ultralong GnRHa therapy on intrafollicular concentrations of tumor necrosis factor alpha (TNFα), oxidative stress markers, and antioxidants in patients with endometriosis. METHODS: Twenty-three infertile women with Stage III or IV endometriosis were recruited for this study. Eleven patients received three courses of GnRHa (1.8 mg s.c. every 28 days), followed by a standard controlled ovarian hyperstimulation (COH) for IVF-ET (ultralong group). The other 12 patients received a standard COH with mid-luteal phase GnRHa down-regulation (control group). The numbers of matured follicles and retrieved oocytes, fertilization rates, implantation rates, clinical pregnancy rate, and intrafollicular concentrations of TNFα, 8-hydroxy-2'-deoxyguanosine (8-OHdG) and hexanoyl-lysine adduct (HEL) as oxidative stress markers, and melatonin and Cu,Zu-superoxide dismutase (Cu,Zn-SOD) as antioxidants were compared between the two groups. RESULTS: The numbers of mature follicles and retrieved oocytes, and fertilization rates did not differ between the two groups. Implantation rates and pregnancy rates tended to be higher in the ultralong group (21.4% and 27.3%, respectively) compared with the control group (8.3% and 8.3%, respectively). TNFα concentrations in the follicular fluid were significantly lower in the ultralong group (5.8 ± 3.2 pg/ml) than those in the control group (10.6 ± 3.2 pg/ml). Follicular concentrations of 8-OHdG concentrations were significantly lower in the ultralong group (5.7 ± 1.6 ng/ml) than those in the control group (6.6 ± 1.5 ng/ml), while melatonin concentrations were significantly higher in the ultralong group (139 ± 46 pg/ml) compared with the control group (86 ± 27 pg/ml). CONCLUSIONS: Ultralong GnRHa therapy reduces the detrimental effects of cytotoxic cytokines and oxidative stress in the ovary in patients with endometriosis.

My notes (saved in your browser only)

Condition tags

mesh:D004715endometriosisinfertility

MeSH descriptors

Biomarkers Endometriosis Fertilization in Vitro Gonadotropin-Releasing Hormone Infertility, Female 8-Hydroxy-2'-Deoxyguanosine Adult Biomarkers Deoxyguanosine Deoxyguanosine Deoxyguanosine Endometriosis Endometriosis Female Fertilization in Vitro Gonadotropin-Releasing Hormone Gonadotropin-Releasing Hormone Gonadotropin-Releasing Hormone Humans Infertility, Female

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (34)

Cited by (41)

Source provenance

europepmc
last seen: 2026-06-04T01:30:01.192114+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:18:15.805398+00:00
License: CC0 · commercial use OK